These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31930057)

  • 1. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes.
    Tovilla-Zárate CA; Pérez-Mandujano A; Ramírez-González IR; Fresan A; Suarez-Mendez S; Martínez-Villaseñor E; Rodríguez-Sánchez E; Villar-Soto M; López-Narváez ML; González-Castro TB; Ble-Castillo JL; Juárez-Rojop IE
    Ann Transl Med; 2019 Nov; 7(22):656. PubMed ID: 31930057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F; Shariati B; Naderi S; Shalbafan M; Mortezaei A; Sahebolzamani E; Saeb A; Hosein Mortazavi S; Kamalzadeh L; Aqamolaei A; Ali Noorbala A; Namazi-Shabestari A; Akhondzadeh S
    J Clin Pharm Ther; 2020 Aug; 45(4):804-811. PubMed ID: 32420649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxetine
    Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
    Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.
    Cao B; Park C; Rosenblat JD; Chen Y; Iacobucci M; Subramaniapillai M; Mansur RB; Zuckerman H; Lee Y; McIntyre RS
    J Psychopharmacol; 2019 Nov; 33(11):1388-1394. PubMed ID: 31530216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial.
    Rossini D; Serretti A; Franchini L; Mandelli L; Smeraldi E; De Ronchi D; Zanardi R
    J Clin Psychopharmacol; 2005 Oct; 25(5):471-5. PubMed ID: 16160624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
    Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.
    Stockler MR; O'Connell R; Nowak AK; Goldstein D; Turner J; Wilcken NR; Wyld D; Abdi EA; Glasgow A; Beale PJ; Jefford M; Dhillon H; Heritier S; Carter C; Hickie IB; Simes RJ;
    Lancet Oncol; 2007 Jul; 8(7):603-12. PubMed ID: 17548243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
    Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
    Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nepeta menthoides Boiss. & Buhse freeze-dried aqueous extract versus sertraline in the treatment of major depression: A double blind randomized controlled trial.
    Kolouri S; Firoozabadi A; Salehi A; Zarshenas MM; Dastgheib SA; Heydari M; Rezaeizadeh H
    Complement Ther Med; 2016 Jun; 26():164-70. PubMed ID: 27261997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.
    Mowla A; Dastgheib SA; Razeghian Jahromi L
    Clin Drug Investig; 2016 Jul; 36(7):539-43. PubMed ID: 27071759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.